The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://imogenazkh888219.wikigop.com/1858566/retatrutide_vs_tirzepatide_a_comparative_analysis